Abstract. The present study aimed to verify a possibility of ongoing lymphangiogenesis in non-small cell lung cancer (NSCLC) via examination of mRNA levels of a number of lymphangiogenesis-associated genes in tumors. It was hypothesized that transcriptional activation of these genes would occur in tumors that stimulate new lymphatic vessel formation. The study was performed on 140 pairs of fresh-frozen surgical specimens of cancer and unaffected lung tissues derived from NSCLC stage I-IIIA patients. mRNA levels were evaluated with the reverse transcription-quantitative polymerase chain reaction method and expressed as fold change differences between the tumor and normal tissues. Possible associations between expression and patient clinicopathological characteristics and survival were analyzed. In the NSCLC tissue samples, vascular endothelial growth factor (VEGF) C, VEGFD, VEGFR3, VEGFR2, VEGFR1, lymphatic vessel endothelial hyaluronan receptor 1, integrin subunit α 9, FOX2, neuropilin 2, fibroblast growth factor 2 genes were significantly downregulated (P<0.001 for all) compared with matched normal lung tissues, whereas mRNA levels for VEGFA, spleen associated tyrosine kinase, podoplanin, and prospero homeobox 1 genes were similar in both tissues. Neither lymph node status, nor disease pathological stage influenced expression, whereas more profound suppression of gene activities appeared to occur in squamous cell carcinomas compared with adenocarcinomas. The VEGFR1 mRNA expression level was significantly connected with patient survival in the univariate analysis, and was an independent prognostic factor for overall survival in the multivariate Cox's proportional hazards model (HR 2.103; 95% confidence interval: 1.005-4.401; P= 0.049). The results support a hypothesis of absence of new lymphatic vessel formation inside growing NSCLC tumor mass, however do not exclude a possibility of lymphangiogenesis in narrow marginal tumor parts.
Introduction
The lymphatic system forms an extensive network of low shear force vessels that penetrates almost all organs of the human body. It plays a key role in the maintenance of tissue-fluid homeostasis and is essential for the immune system functioning (1) . Lymphatic vasculature has long been considered one of the main routes of solid tumors metastatic dissemination to distant organs (2, 3) . Highly-permeable and comparatively wide lymphatic capillaries seem to be well accommodated to tumor cell transport from the primary tumor mass into the blood circulation. Sentinel lymph nodes that directly drain primary tumors are usually the first sites of detectable metastases. Histological examination of these and nearby lymph nodes is routinely used for determining the stage of disease progression and for prediction of patients' survival (4) . Moreover, it has become clear that lymphatics profoundly affects cancer progression (5) . Growing evidence indicates that direct modulation of immune cell functions by lymphatic endothelial cells (LECs) may be essential for both antitumor immune response at early stages of tumor progression and subsequent cancer-induced immunosuppression (6) . Based on these assumptions, it has been proposed that tumors may stimulate formation of new lymphatic vessel via process of lymphangiogenesis in a manner analogous to tumor angiogenesis, thereby promoting both tumorigenesis and lymphagenous metastasis (3, 5, 7) .
Evidence for ongoing lymphangiogenesis inside growing tumors was initially provided from animal studies. In experimental models of cancer, forced formation of intratumor lymphatic vasculature increased tumor aggressiveness and facilitated metastatic spread (8) (9) (10) (11) , while inhibition of the lymphangiogenesis prevented lymph node and distant metastases without significantly affecting primary tumor growth (12, 13) . In agreement with these data, numerous clinical studies demonstrated an association between tumor expression of lymphatic-specific growth factors or lymph vessel density and tumor progression or poor patient survival (14) (15) (16) . However, a lack of the correlation as well
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as an absence of proliferating LECs in the primary tumors were reported by others (17, 18) . Moreover, detailed histological analyses of various solid tumors frequently failed to reveal lymphatic vessels throughout tumor masses except the periphery of these tumors (19) (20) (21) , suggesting a lack of ongoing lymphangiogenesis. Besides, growing evidence suggests that lymphatics suppression might be favorable for tumor growth at early stages of cancer progression due to anti-tumor immune response weakening (22) . Thus, formation of new lymphatic vessels in growing human tumors remains an unresolved question. In order to evaluate a probability of lymphangiogenesis induction in non-small cell lung cancer (NSCLC), we performed a comprehensive analysis of the transcriptional activity of 15 genes encoding lymphatics regulators or markers (23) (24) (25) (26) . Using a comparative quantitative polymerase chain reaction (qPCR) method we examined the expression at mRNA level of the vascular endothelial growth factors: VEGFA, VEGFC, and VEGFD/FIFG, their receptors: VEGFR1/FLT1, FEGFR2/KDR, and VEGFR3/FLT4 and co-receptors neuropilin 2 (NRP2) and integrin a9 subunit (ITG9), basic fibroblast growth factor 2 (FGF2), transcription factors: prospero-related homeobox domain 1 (PROX1) and Forkhead box C2 (FOXC2), lymphatic-specific membrane proteins: lymphatic vessel hyaluronan receptor 1 (LYVE1) and glomerular podocyte mucoprotein podoplanin (PDPN), spleen protein kinase (SYK) and key component of desmosomal plaque proteins: desmoplakin (DSP). A brief characteristics of the analyzed factors is presented in Table I . Transcript levels were evaluated by comparison to those in non-malignant lung tissue and analyzed in terms of patients' clinicopathological characteristics.
Materials and methods
Patients and samples. The study was performed on 140 pairs of tumor and matched unaffected lung tissue specimens obtained from I-IIIA stage NSCLC patients who underwent a curative surgery at the Bialystok Medical University Hospital between 2000 and 2010. Disease staging was performed according to the seventh edition of the tumor-nodes-metastasis system (TNM) for lung cancer (27) . None of the patients received chemo-or radiotherapy before the surgery. All of them gave the written informed consent for specimen collection and clinicopathological data processing. The study design was approved by the Ethics Committee of the University.
Tissue samples were collected intraoperatively and processed immediately after surgical removal according to the systematic biobanking quality (28) . After the macroscopic visual assessment, the tumors were divided into two sections. One of them was fixed in formalin followed by paraffin embedding, and the other was divided into small pieces (approximately 0.5 cm in diameter) and frozen in liquid nitrogen followed by storage at -80˚C. Unaffected lung parenchyma specimens were dissected from the same lobe or lung of the patient at an area at least 5 cm distant from the tumor and processed similarly to tumor specimens. Prior to RNA extraction, the cross-sections of frozen tissue samples were stained with hematoxylin-eozyn and evaluated by an experienced pathologist (L.C.) to confirm the suitability of cell content. Namely, tumor specimens with the highest percentage of the malignant cells (but at least 60% of tumor cells on a microscopic section) and normal lung epithelium without metaplasia or dysplasia were used for further processing. (30) . To examine possible associations between gene activity and patients' clinicopathological characteristics or survival, log 2 FC values were used. For survival analysis a median log 2 FC for each gene was used as a cutoff and the expression was categorized as high (equal or higher than the median) or low (lower than the median).
RNA
Statistical analysis. The differences in mRNA expression levels between the tumor and unaffected lung tissues were analyzed with paired Wilcoxon rank-sum test. The Wilcoxon rank-sum or Kruskal-Wallis rank tests were used to analyze the associations between clinicopathological characteristics and mRNA expression levels. OS was calculated and plotted with Kaplan-Meier method with the log-rank test for comparison between the groups. Cox proportional hazards method was used to evaluate the effect of clinicopathological and molecular variables on OS. P<0.05 was considered to indicate a statistically significant difference. All the statistical analyses in this study were performed using STATA/SE 11.1 software (Stata Corporation, College Station, TX, USA.
Results

Patient characteristics.
A total of 140 NSCLC patients, aged from 39 to 79 years (mean 62, standard deviation 8.0 years), were included in the study. The majority of the patients (117 out of 140, 84%) were males. Among the patients, 57 (41.4%) had lung adenocarcinoma (ADC), 66 (47.1%) had squamous cell carcinoma (SCC), and the remaining 17 (11.4%) had large cell lung carcinoma (LCC). Forty-five tumors were recognized as highly differentiated (grade 1 or 2), and fifty-five were lowly differentiated ones (grade 3 or 4). Lymph node metastasis was (Table II) .
Associations between transcript level and clinicopathological characteristics. The analysis of the effect of patients' clinicopathological features on gene expression revealed a relatively limited and differentiated influence on the fold-change values. In particular, tumor-associated downregulation of the expression for VEGFC (P= 0.049), VEGFR3 (P= 0.107), VEGFR2 (P=0.028), and ITGA (P= 0.011) genes was higher in SCC than in ADC or LCC, and two genes (PROX1 and VEGFA) were downregulated in SCC but not in non-squamous histological types (P=0.005 and P=0.012 for PROX1 and VEGFA, respectively) (Fig. 1A-F) . In larger tumors, suppression of VEGFR3 and LYVE1 activity was more significant than those in smaller ones (P= 0.034 and P= 0.50 for VEGFR3 and LYVE1, respectively), whereas the opposite relation was revealed for PDPN and NRP2 genes (P=0.019 and P=0.019, respectively) ( Fig. 2A-D) . However, we failed to find associations between the analyzed mRNA levels and lymph node metastases or disease stage. PDPN (P= 0.049), SYK (P<0.001) and FGF2 (P=0.041) transcriptional downregulation was more significant in high-graded tumors (G3 or G4) compared with low-graded ones (G1 or G2) (Fig. 3A-C) . Although unchanged in the whole cohort of our patients or in men, VEGFA expression was upregulated in tumors derived from women (P=0.020) (Fig. 4A) . In addition, more significant suppression of FGF2 (P= 0.012), VEGFR2 (P= 0.045), and ITGA (P= 0.005) transcription was observed in men compared to women (Fig. 4B-D) .
The effects of gene expression level on patients' survival.
The median follow-up time was equal to 54.6 months (ranged from 2 to 86 months). During the follow-up, 64 (45.6%) patients had disease recurrence and all of them had died. In the Kaplan-Meier curve analysis, none of the analyzed parameters influenced OS, except VEGFR1 expression. The OS rate of the patients with low VEGFR1 expression was significantly shorter than that of the patients with high expression level (P=0.045). In multivariate analysis by Cox's proportional hazards method, low VEGFR1 expression was an independent prognostic factor for a poor OS time (HR 2.103; 95% CI: 1.005-4.401; P= 0.049) (Table III) .
Discussion
NSCLC remains one of the most life-threatening human malignances (31), mostly due to early metastasis Table II occurrence (32) . Although lymphatic system has long been considered one of the main routes of cancer cell dissemination to distant organs (2,3), an issue of new lymphatic vessel formation in solid tumors, including lung cancer, remains unresolved (33) . The aim of the present study was to examine a possible impact of lung cancer cells on lymphangiogenesis induction within lung tumor mass. To do that we, firstly, analyzed mRNA expression level of well-established lymphangiogenesis inductors and markers (namely, VEGFC, VEGFD, VEGFR3, LYVE1, PDPN) and also of a number of pleiotrophic factors with reported contribution to the process (VEGFA, FGF2, NRP2, PROX1 and others). Secondly, although we did not perform tissue microdissection to exclude the influence of nonmalignant stromal cells on the analyzed parameters, we used lung cancer tissue specimens enriched in malignant cells (a median cancer cell content was 80%, ranged from 60 to 100%). Thirdly, we compared the expression level of the examined genes in tumors with that in the nonmalignant lung tissue derived from the same patient. We assumed that transcriptional activation (an increase in transcript level in tumors compared with paired unaffected lung tissues) of the genes essential for lymphatic vessel formation, reorganization and maintenance had to be observed in lymphangiogenesis-inducing tumors. Despite expectations, none of the analyzed genes, except DSP, was activated in tumor tissue. Moreover, in malignant tissues, a statistically significant decrease in transcript level was observed for growth factors VEGFC and VEGFD and their receptor VEGFR3 that are thought to be the most potent inductors of lymphatic vessel formation (10, 34, 35) , and transcripts for lymphatics-specific markers LYVE1 (36,37) and FOXC2 (38) . The expression levels of other well-estimated lymphatic molecules PDPN (39, 40) and PROX1 (41, 42) were similar to those in nonmalignant tissue. Moreover, neither lymph node status, nor disease stage influenced transcript level for these genes, while more significant suppression of gene activity seemed to occur in SCC, compared to ADC or LCC. Also, no impact of aforementioned genes on patients' survival was observed. Thus, our results do not confirm a hypothesis of lymphangiogenesis induction in NSCLC, but instead seem to indicate a possible transcriptional suppression of the process.
Si m i la r r esu lt s wer e r e c ent ly publ ishe d by Sanmartín et al (43) , who analyzed the mRNA expression of all the VEGF family members, their receptors and co-receptors NRP1 and NRP2 in early-stage NSCLCs. The authors applied a similar methodological approach for mRNA evaluation and indicated significantly lower levels of VEGFD, VEGFR2, and VEGFR3 mRNA in tumors, especially remarkable in the case of VEGFD transcripts. Unfortunately, no information about the remaining analyzed genes has been reported by authors (43) . Lower VEGFC and similar VEGFR3 mRNA expression levels in NSCLC tissues compared with normal lung tissues were also indicated by Takizawa et al (44) . However, in another study, a differentiated VEGFC and VEGFD expression across tumor mass was indicated. In this analysis, a significantly reduced VEGFC and VEGFD mRNA expression was indicated in central tumor regions compared with the corresponding non-tumor lung tissues. However, in external tumor marginal regions, the mRNA level was found to be similar (for VEGFC transcripts) or even higher (for VEGFD transcripts) than those in non-tumoral tissues. Immunohistochemical examination confirmed these data. Moreover, the number of D2-40-immunostained lymphatic vessels was much higher at tumor periphery than in the central zone, and correlated with VEGFC and VEGFD mRNA levels (45) . These results suggest that formation of new lymphatic vessels in NSCLC may be restricted to the peripheral tumor zones. In the present study, we did not analyze separately internal and external tumor zones. Instead, specimens of bulk tumor mass enriched in malignant cells were used for transcript evaluation. In our opinion, our results do not confirm an induction of new lymphatic vessels formation in NSCLC.
We also failed to indicate associations between VEGFC, VEGFD or VEGFR3 mRNA expression and lymph node metastasis or patients' prognosis. Our data are partially consistent with previously reported observations, although in terms of the expression at mRNA level, limited and opposite data have also been reported. Thus, no associations between VEGFC and VEGFR3 expression and lymph node status or patients' survival were indicated by Maekawa et al (46) , whereas Takizawa et al (44) and Li et al (47) reported similar data for VEGFC and VEGFR3 expression, respectively. In contrast, Takizawa et al (44) indicated significantly lower VEGFR3 mRNA levels in the node-positive group and an inverse relation in terms of VEGFC/VEGFR3 expression ratios. In respect to VEGFD, a negative correlation was found between VEGFD mRNA under-expression in NSCLC and lymph node metastasis (43, 46) . In contrast, Feng et al (45) indicated a positive correlation between VEGFC or VEGFD mRNA expression and lymph node metastases, but only in terms of the invasive marginal tumor regions.
Although studies on VEGFC, VEGFD, and VEGFR3 expression at mRNA level are limited, protein expression in NSCLC cells has been examined extensively by immunohistochemistry. A number of recent meta-analyses that summarize the results of these clinical investigations preferentially indicate positive VEGFC/D and VEGFR3 immunostaining in tumor cells and a positive correlation between the expression level and lymph node involvement or disease progression (48, 49) . Similar data were obtained for breast, colorectal and esophageal cancer patients (50) (51) (52) . However, in all the reports, significant discrepancies across particular studies have been highlighted. In our opinion, currently, there is no data to clearly support or oppose new lymphatic vessel formation in NSCLC.
In terms of the remaining genes examined in the present study, it is difficult to compare our results to previously reported data. Protein products of these genes have been demonstrated to be implicated in lymphatic system development, reorganization and maintenance in both physiological and pathological conditions (24) (25) (26) 34) and are widely used as markers for microscopic imaging of lymphatic vessels (40, 53) . However, in addition to lymphatics, these protein are expressed in various cell types and contribute to multiple molecular processes, including those in malignancies, as it has been demonstrated in a number of recent comprehensive reviews (54) (55) (56) (57) (58) (59) (60) (61) (62) . This may provide an explanation for inconsistent data on the expression of analyzed proteins in cancer and their impact on tumor progression and clinical outcome (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) .
For one of the genes, namely DSP, encoded for desmoplakin, an increase in mRNA level in NSCLC has been demonstrated. Desmoplakin is one of the main components of desmosomes that confer strong cell-cell adhesion and tissue resistance against mechanical stress but are also involved in cell proliferation, differentiation migration, morphogenesis and apoptosis (57, 58) . A body of evidence indicates that desmosomal proteins are deregulated in various cancers and the deregulation contributes to cancerogenesis (58) . Although a tumor-suppressive function of desmosomal proteins has mainly been postulated, discrepant data in the literature indicate that differential changes in their expression in tumor tissue may occur and possibly have different consequences (58) .
Among the genes we examined here, there were those for growth factor VEGF and their receptors VEGFR1 and VEGFR2. VEGFA/VEGFR1-2 signaling is considered a key inductor of physiological and tumor-associated angiogenesis (78) . Recently, VEGFA and VEGFR2 have also been implicated in tumor lymphangiogenesis (3, 5, 33, 34) . Of interest, a number of clinical NSCLC studies demonstrated a positive correlation between high tumor cell VEGFA expression and lymph node metastasis (79, 80) and an inverse association in terms of stromal cell VEGFA expression (80) . In our study, we failed to demonstrate VEGFAVEGFR1-2 signaling up-regulation in NSCLC, and these data seem to be discordant with a widely accepted view on angiogenesis induction in cancers (81) . However, a gross of other factors have been found to stimulate new blood vessel formation, and tumors with VEGFA-independent angiogenesis (82, 83) or those co-opting preexisting vessels have been frequently indicated (84, 85) .
In our study, VEGFR1 mRNA expression level seemed to be linked to patients' survival (P=0,049). However, further investigations on larger patients cohort are needed to confirm this possibility. VEGFR1 is an alternative VEGFA receptor which also binds VEGFB and placental growth factor PIGF (78, 86) . The prognostic value of this receptor expression in NSCLC remains controversial. In several recent studies, an unfavorable effect of high VEGFR1 expression on NSCLC patient' survival has been demonstrated (87, 49) , whereas others found no correlation between the expression and the prognosis of the disease (88) . To resolve discrepancies in the results further investigations are needed.
An important conclusion raising from our analysis reveals possible differences between NSCLC histological types in lymphangiogenesis regulation which are known to exist regarding new blood vessel formation and are taken into account in targeted antivascular therapy. �e indicated a signifi -. �e indicated a significantly lower VEGFC, VEGFR2, VEGFR3, and PROX1 mRNA expression in SCC compared with non-squamous NSCLC histological types, that suggests a more profound suppression of lymphangiogenesis in SCC and is in line with Takizawa et al data according to VEGFC and VEGFR3 mRNA levels (44) .
In summary, our results demonstrate that the expression of the lymphangiogenesis-promoting factors in NSCLC cells seem to be suppressed at mRNA level early in cancer progression and more profoundly in SCC compared with ADC or LCC. These findings are in accordance with a recent hypothesis of absence of ongoing lymphangiogenesis inside a growing tumor mass, but do not exclude a possibility of lymphangiogenesis in narrow marginal tumor regions and a contribution of this lymphatics to lymph node metastasis. On the other hand, in the light of current knowledge on crosstalk between lymphatic and immune cells, our data may suggest a possibility of repression of active lymphatic function by tumor cells in order to reduce anti-tumor immunity. Of course, the some factors we had analyzed in the present study, are not limited only to lymphatic system development and functioning, but may play other multiple roles in both tumor and stromal cells, and alterations in their expression may depend on tumor biological characteristics and progression stage. 
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